Search

Your search keyword '"Silva, Clovis A."' showing total 1,588 results
Start Over Author "Silva, Clovis A."
1,588 results on '"Silva, Clovis A."'

2. Development of clinical and laboratory biomarkers in an international cohort of 428 children with lupus nephritis

Author

De Mutiis, Chiara, Wenderfer, Scott E., Basu, Biswanath, Bagga, Arvind, Orjuela, Alvaro, Sar, Tanmoy, Aggarwal, Amita, Jain, Avinash, Boyer, Olivia, Yap, Hui-Kim, Ito, Shuichi, Ohnishi, Ai, Iwata, Naomi, Kasapcopur, Ozgur, Laurent, Audrey, Chan, Eugene Yu-hin, Mastrangelo, Antonio, Ogura, Masao, Shima, Yuko, Rianthavorn, Pornpimol, Silva, Clovis A., Trindade, Vitor, and Tullus, Kjell

Published
2024
Full Text
View/download PDF

5. Childhood-onset systemic lupus erythematosus (cSLE) and malignancy: a nationwide multicentre series review

Author

Brufatto, Matheus Zanata, Lanças, Sean Hideo Shirata, de Albuquerque Pedrosa Fernandes, Taciana, Sallum, Adriana Maluf Elias, Campos, Lucia Maria Arruda, Sakamoto, Ana Paula, Terreri, Maria Teresa, Sztajnbok, Flavio Roberto, Bica, Blanca Elena Rios Gomes, Ferriani, Virginia Paes Leme, de Carvalho, Luciana Martins, Silva, Clovis Artur Almeida, and Saad-Magalhaes, Claudia

Published
2024
Full Text
View/download PDF

7. Robust immunogenicity to the H3N2 component of influenza A vaccine in primary Sjögren syndrome

Author

Pasoto, Sandra Gofinet, Borba, Eduardo Ferreira, Formiga, Francisco Fellipe Claudino, do Nascimento Pedrosa, Tatiana, Aikawa, Nadia Emi, de Siqueira, Marilda Agudo Mendonça Teixeira, Capão, Artur Silva Vidal, de Proença, Adriana Coracini Tonacio, Fuller, Ricardo, Yuki, Emily Figueiredo Neves, Leon, Elaine Pires, de Oliveira Martins, Victor Adriano, Lopes, Marta Heloisa, da Silva Duarte, Alberto José, da Silva, Clovis Artur Almeida, and Bonfa, Eloisa

Published
2023
Full Text
View/download PDF

9. Safety and immunogenicity of influenza A(H3N2) component vaccine in juvenile systemic lupus erythematosus

Author

Aikawa, Nadia Emi, Borba, Eduardo Ferreira, Balbi, Verena Andrade, Sallum, Adriana Maluf Elias, Buscatti, Izabel Mantovani, Campos, Lucia Maria Arruda, Kozu, Kátia Tomie, Garcia, Cristiana Couto, Capão, Artur Silva Vidal, de Proença, Adriana Coracini Tonacio, Leon, Elaine Pires, da Silva Duarte, Alberto José, Lopes, Marta Heloisa, Silva, Clovis Artur, and Bonfá, Eloisa

Published
2023
Full Text
View/download PDF

10. Post-acute COVID-19 in three doses vaccinated autoimmune rheumatic diseases patients: frequency and pattern of this condition

Author

Silva, Clovis Artur, de Vinci Kanda Kupa, Leonard, Medeiros-Ribeiro, Ana Cristina, Pasoto, Sandra Gofinet, Saad, Carla Gonçalves Schahin, Yuki, Emily Figueiredo Neves, Landim, Joaquim Ivo Vasques Dantas, Léda, Victor Hugo Ferreira e, de Camargo Correia, Luisa Sacchi, Sartori, Artur Fonseca, Martins, Carolina Campagnoli Machado Freire, Ribeiro, Carolina Torres, Waridel, Filipe, de Oliveira Martins, Victor Adriano, Shinjo, Samuel Katsuyuki, Andrade, Danieli Castro Oliveira, Sampaio-Barros, Percival Degrava, Neto, Eduardo Ferreira Borba, Aikawa, Nadia Emi, and Bonfa, Eloisa

Published
2023
Full Text
View/download PDF

11. Chronic kidney disease in patients with childhood-onset systemic lupus erythematosus

Author

Sakamoto, Ana P., Silva, Clovis A., Islabão, Aline G., Novak, Glaucia V., Molinari, Beatriz, Nogueira, Paulo K., Pereira, Rosa M. R., Saad-Magalhães, Claudia, Clemente, Gleice, Piotto, Daniela P., Aikawa, Nadia E., Pitta, Ana C., Trindade, Vitor C., Appenzeller, Simone, Carvalho, Luciana M., Rabelo-Junior, Carlos N., Fonseca, Adriana R., Sztajnbok, Flavio R., Santos, Maria C., Bica, Blanca E., Sena, Evaldo G., Moraes, Ana J., Fraga, Melissa M., Robazzi, Teresa C., Spelling, Paulo F., Scheibel, Iloite M., Cavalcanti, Andre S., Matos, Erica N., Guimarães, Luciano J., Santos, Flavia P., Mota, Licia M. H., Bonfá, Eloisa, and Terreri, Maria T.

Published
2023
Full Text
View/download PDF

12. International cohort of 382 children with lupus nephritis – presentation, treatment and outcome at 24 months

Author

De Mutiis, Chiara, Wenderfer, Scott E., Basu, Biswanath, Bagga, Arvind, Orjuela, Alvaro, Sar, Tanmoy, Aggarwal, Amita, Jain, Avinash, Yap, Hui-Kim, Teo, Sharon, Ito, Shuichi, Ohnishi, Ai, Iwata, Naomi, Kasapcopur, Ozgur, Yildiz, Mehmet, Laurent, Audrey, Mastrangelo, Antonio, Ogura, Masao, Shima, Yuko, Rianthavorn, Pornpimol, Silva, Clovis A., Trindade, Vitor, Gianviti, Alessandra, Akinori, Miyazono, Hamada, Riku, Fujimura, Junya, Minamikawa, Shogo, Kamiyoshi, Naohiro, Kaito, Hiroshi, Ishimori, Shingo, Iannuzzella, Francesco, and Tullus, Kjell

Published
2023
Full Text
View/download PDF

13. High Fatality Rates in Pediatric Multisystem Inflammatory Syndrome: A Multicenter Experience From the Epicenter of Brazil’s Coronavirus Pandemic

Author

Almeida, Flávia Jacqueline, Jarovsky, Daniel, Almeida Farias, Camila Giuliana, Ramos Nantes de Castilho, Taisa Roberta, Gara Caetano, Thiago, Manzoni Ribeiro Borsetto, Cibele Cristina, Simões Aguiar, Andressa, Serafini de Araújo, Carolina, Badue Pereira, Maria Fernanda, de Sousa Marques, Heloisa Helena, Silva, Clovis Artur, Ribeiro de Matos Tannure, Andressa, Prado, Rogério, Becker Mau, Luciana, Andrade Alvares, Paula, de Siqueira, Antônio Carlos, Paro Scremin, Gustavo, Otsuka, Marcelo, Volpe Arnoni, Mariana, Machado Rissoni Laporte, Roberta, Altruda de Moraes Costa Carlesse, Fabianne, Ejzenberg, Fernanda, Naaman Berezin, Eitan, and Palazzi Sáfadi, Marco Aurélio

Published
2024
Full Text
View/download PDF

14. Clinical features, treatment and outcome of pediatric patients with severe cutaneous manifestations in IgA vasculitis: Multicenter international study

Author

Sestan, Mario, Kifer, Nastasia, Sozeri, Betul, Demir, Ferhat, Ulu, Kadir, Silva, Clovis A., Campos, Reinan T., Batu, Ezgi Deniz, Koker, Oya, Sapina, Matej, Srsen, Sasa, Held, Martina, Gagro, Alenka, Fonseca, Adriana Rodrigues, Rodrigues, Marta, Rigante, Donato, Filocamo, Giovanni, Baldo, Francesco, Heshin-Bekenstein, Merav, Giani, Teresa, Kataja, Janne, Frkovic, Marijan, Ruperto, Nicolino, Ozen, Seza, and Jelusic, Marija

Published
2023
Full Text
View/download PDF

15. COVID-19 quarantine in adolescents with autoimmune rheumatic diseases: mental health issues and life conditions

Author

Ihara, Bianca P., Lindoso, Lívia M., Setoue, Debora N. D., Tanigava, Nicolas Y., Helito, Alberto C., Simon, Juliana R., Viana, Vivianne S. L., Strabelli, Claudia A. A., Pedroso, Camilla A. A., Sieczkowska, Sofia M., Pereira, Rosa M. R., Aikawa, Nádia E., Kozu, Katia T., Elias, Adriana M., Buscatti, Izabel M., Gualano, Bruno, Queiroz, Ligia B., Casella, Caio B., Polanczyk, Guilherme V., Silva, Clovis A. A., and Campos, Lucia M. M. A.

Published
2022
Full Text
View/download PDF

16. Lupus Nephritis

Author

Wenderfer, Scott, Mason, Sherene, Bernal, Christine, da Silva, Clovis Artur Almeida, Emma, Francesco, editor, Goldstein, Stuart L., editor, Bagga, Arvind, editor, Bates, Carlton M., editor, and Shroff, Rukshana, editor

Published
2022
Full Text
View/download PDF

17. Major discrepancy between clinical diagnosis of death and anatomopathological findings in adolescents with chronic diseases during 18-years

Author

Ribeiro, Maira P., Duarte-Neto, Amaro N., Dolhnikoff, Marisa, Lindoso, Livia, Lourenço, Benito, Marques, Heloisa H., Pereira, Maria F.B., Cristofani, Lilian M., Odone-Filho, Vicente, Campos, Lucia M.A., Sallum, Adriana M.E., Carneiro-Sampaio, Magda, Delgado, Artur F., Carvalho, Werther B., Mauad, Thais, and Silva, Clovis A.

Published
2023
Full Text
View/download PDF

18. Emotional, hyperactivity and inattention problems in adolescents with immunocompromising chronic diseases during the COVID-19 pandemic

Author

Campos, Reinan T., Lindoso, Livia, Sousa, Renan A. de, Helito, Alberto C., Ihara, Bianca P., Strabelli, Claudia A.A., Paradelas, Levi M.V., Carneiro, Beatriz O.L., Cardoso, Maria Paula R., Souza, Jean Paulo V. de, Freire, Marianna R. de M., Astley, Camilla, Laurentino, Moisés F., Buscatti, Izabel M., Kozu, Katia, Aikawa, Nadia E., Sallum, Adriana M.E., Ferreira, Juliana C.O., Simon, Juliana R., Viana, Vivianne S.L., Queiroz, Ligia B., Gualano, Bruno, Roschel, Hamilton, Pereira, Rosa Maria R., Toma, Ricardo K., Watanabe, Andréia, Grangeiro, Patricia M., Casella, Caio B., Farhat, Sylvia C., Polanczyk, Guilherme V., Campos, Lucia Maria A., and Silva, Clovis A.

Published
2023
Full Text
View/download PDF

19. Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose

Author

Pereira, Rosa M.R., Dagostin, Marilia A., Caparbo, Valeria F., Sales, Lucas P., Pasoto, Sandra G., Silva, Clovis A., Yuki, Emily F.N., Saad, Carla G.S., Medeiros-Ribeiro, Ana C., Kupa, Leonard V.K., Fusco, Solange R.G., Martins, Victor A.O., Martins, Carolina C.M.F., Barbas, Carmen Valente, Shinjo, Samuel K., Aikawa, Nadia E., and Bonfa, Eloisa

Published
2023
Full Text
View/download PDF

20. Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis

Author

G.S. Saad, Carla, S.R. Silva, Matheus, Sampaio-Barros, Perceval D., C.B. Moraes, Julio, G. Schainberg, Cláudia, Gonçalves, Celio R., Shimabuco, Andrea Y., Aikawa, Nadia E., F.N. Yuki, Emily, G. Pasoto, Sandra, V.K. Kupa, Leonard, K. Aoyama, Renato, S.R. Araujo, Carlo, Silva, Clóvis A., Medeiros-Ribeiro, Ana C., and Bonfa, Eloisa

Published
2023
Full Text
View/download PDF

21. Inactivated SARS-CoV-2 vaccine in primary Sjögren’s syndrome: humoral response, safety, and effects on disease activity

Author

Pasoto, Sandra Gofinet, Halpern, Ari Stiel Radu, Guedes, Lissiane Karine Noronha, Ribeiro, Ana Cristina Medeiros, Yuki, Emily Neves Figueiredo, Saad, Carla Gonçalves Schahin, da Silva, Clovis Artur Almeida, de Vinci Kanda Kupa, Léonard, Villamarín, Lorena Elizabeth Betancourt, de Oliveira Martins, Victor Adriano, Martins, Carolina Campagnoli Machado Freire, Deveza, Giordano Bruno Henriques, Leon, Elaine Pires, Bueno, Cleonice, Pedrosa, Tatiana Nascimento, Santos, Roseli Eliana Beseggio, Soares, Renata, Aikawa, Nádia Emi, and Bonfa, Eloisa

Published
2022
Full Text
View/download PDF

22. No Associations Between Physical Activity and Immunogenicity in SARS-CoV-2 Seropositive Patients With Autoimmune Rheumatic Diseases Prior to and After Vaccination.

Author

Smaira, Fabiana Infante, Mazzolani, Bruna Caruso, Lemes, Ítalo Ribeiro, da Silva, Rafael Pires, Pinto, Ana J., Sieczkowska, Sofia M., Aikawa, Nadia E., Pasoto, Sandra G., Medeiros-Ribeiro, Ana C., Saad, Carla G.S., Yuk, Emily F.N., Silva, Clovis A., Swinton, Paul, Kupa, Leonard de Vinci Kanda, Hallal, Pedro C., Roschel, Hamilton, Gualano, Bruno, and Bonfa, Eloisa

Subjects
IMMUNE response, RHEUMATISM, PHYSICAL activity, NATURAL immunity, SARS-CoV-2
Abstract

Aim: To investigate the association between physical activity and immunogenicity among SARS-CoV-2 seropositive patients with autoimmune rheumatic diseases prior to and following a 2-dose schedule of CoronaVac (Sinovac inactivated vaccine). Methods: This was a prospective cohort study within an open-label, single-arm, phase 4 vaccination trial conducted in Sao Paulo, Brazil. In this substudy, only SARS-CoV-2 seropositive patients were included. Immunogenicity was assessed by seroconversion rates of total anti-SARS-CoV-2 S1/S2 immunoglobulin G (IgG), geometric mean titers of anti-S1/S2 IgG, frequency of positive neutralizing antibodies, and neutralizing activity before and after vaccination. Physical activity was assessed through a questionnaire. Model-based analyses were performed controlling for age (<60 or ≥60 y), sex, body mass index (<25, 25–30, and >30 kg/m2), and use of prednisone, immunosuppressants, and biologics. Results: A total of 180 seropositive autoimmune rheumatic disease patients were included. There was no association between physical activity and immunogenicity before and after vaccination. Conclusions: This study suggests that the positive association between physical activity and greater antibody responses seen in immunocompromised individuals following vaccination is overridden by previous SARS-CoV-2 infection, and does not extend to natural immunity. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Spotlight on latent tuberculosis infection screening for juvenile idiopathic arthritis in two countries, comparing high and low risk patients

Author

Piotto, Daniela, Nicacio, Aline, Neto, Agna, Mourão, Ana Filipa, Oliveira-Ramos, Filipa, Campanilho-Marques, Raquel, Guedes, Margarida, Cabral, Marta, Santos, Maria José, Fonseca, João Eurico, Canhão, Helena, Aikawa, Nádia Emi, Oliveira, Sheila K. F., Ferriani, Virginia P. L., Pileggi, Gecilmara C. S., Magalhães, Claudia S., Silva, Clovis Artur, and Terreri, Maria Teresa

Published
2022
Full Text
View/download PDF

26. Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients

Author

Silva, Clovis A., Medeiros-Ribeiro, Ana C., Kupa, Leonard V. K., Yuki, Emily F. N., Pasoto, Sandra G., Saad, Carla G. S., Fusco, Solange R. G., Pereira, Rosa M. R., Shinjo, Samuel K., Halpern, Ari S. R., Borba, Eduardo F., Souza, Fernando H. C., Guedes, Lissiane K. N., Miossi, Renata, Bonfiglioli, Karina R., Domiciano, Diogo S., Shimabuco, Andrea Y., Andrade, Danieli C. O., Seguro, Luciana P. C., Fuller, Ricardo, Sampaio-Barros, Percival D., Assad, Ana P. L., Moraes, Julio C. B., Goldenstein-Schainberg, Claudia, Giardini, Henrique A. M., Silva, Henrique C., Martins, Victor A. O., Villamarin, Lorena E. B., Novellino, Renata S., Sales, Lucas P., Araújo, Carlo S. R., Silva, Matheus S. R., Filho, Dilson M. N., Lopes, Marta H., Duarte, Alberto J. S., Kallas, Esper G., Aikawa, Nadia E., and Bonfa, Eloisa

Published
2022
Full Text
View/download PDF

28. Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases

Author

Gualano, Bruno, Lemes, Italo R., Silva, Rafael P., Pinto, Ana J., Mazzolani, Bruna C., Smaira, Fabiana I., Sieczkowska, Sofia M., Aikawa, Nadia E., Pasoto, Sandra G., Medeiros-Ribeiro, Ana C., Saad, Carla G.S., Yuki, Emily F.N., Silva, Clovis A., Swinton, Paul, Hallal, Pedro C., Roschel, Hamilton, and Bonfa, Eloisa

Published
2022
Full Text
View/download PDF

29. Sicca syndrome/Sjögren's disease associated with cancer immunotherapy: a narrative review on clinical presentation, biomarkers, and management.

Author

Pasoto, Sandra Gofinet, Franco, André Silva, Silva, Clovis Artur, and Bonfa, Eloisa

Subjects
SJOGREN'S syndrome, IMMUNE checkpoint inhibitors, DRY eye syndromes, SALIVARY glands, B cells
Abstract

Introduction: Almost one-quarter of immune checkpoint inhibitor (ICI) recipients experience sicca syndrome, while Sjögren's disease (SjD) is estimated at 0.3–2.5%, possibly underreported. Areas covered: This narrative review (Medline/Embase until January/31/2024) addresses the pathophysiology, incidence, demographic/clinical features, biomarkers, labial salivary gland biopsy (LSGB), fulfillment of the idiopathic SjD (iSjD) classificatory criteria, differential diagnosis, and management of sicca syndrome/SjD associated with ICIs. Expert opinion: SjD associated with ICIs is underdiagnosed, since studies that performed the mandatory SjD investigation identified that 40–60% of patients with sicca syndrome associated with ICIs meet the iSjD classificatory criteria. LSGB played a fundamental role in recognizing these cases, as most of them had negative anti-Ro/SS-A antibody. Despite the finding of focal lymphocytic sialoadenitis in LSGB samples mimicking iSjD, immunohistochemical analysis provided novel evidence of a distinct pattern for sicca syndrome/SjD associated with ICIs compared to iSjD. The former has scarcity of B lymphocytes, which are a hallmark of iSjD. Additionally, patients with sicca syndrome/SjD associated with ICIs have demographical/clinical/serological and treatment response dissimilarities compared to iSjD. Dryness symptoms are more acute in the former than in iSjD, with predominance of xerostomia over xerophthalmia, and partial/complete response to glucocorticoids. Dryness symptoms in ICI-treated patients warrant prompt SjD investigation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Long‐Term Follow‐Up of Anti‐Infliximab Antibodies in Patients With Radiographic Axial Spondyloarthritis: A Marker of Drug Survival and Tapering.

Author

Pimentel, Clarissa Q., Medeiros‐Ribeiro, Ana Cristina, Shimabuco, Andrea Y., Sampaio‐Barros, Percival D., Moraes, Júlio César B., Schainberg, Claudia G., Gonçalves, Celio Roberto, Leon, Elaine P., Kupa, Léonard De Vinci K., Pasoto, Sandra G., Aikawa, Nádia E., Silva, Clovis A., Bonfa, Eloisa, and Saad, Carla G. S.

Subjects
ANTI-inflammatory agents, RESEARCH funding, ANKYLOSIS, DRUG therapy, METHOTREXATE, RETROSPECTIVE studies, DESCRIPTIVE statistics, DECISION making in clinical medicine, ANTIBODY formation, LONGITUDINAL method, DRUG efficacy, MEDICAL records, ACQUISITION of data, SPONDYLOARTHROPATHIES, INFLIXIMAB, GENERIC drug substitution, TREATMENT failure, CONFIDENCE intervals, BIOAVAILABILITY, PATIENT aftercare, BIOMARKERS, DRUG tolerance
Abstract

Objective: The aim of this study was to evaluate the influence of anti‐infliximab (IFX) antibodies on three different points of care: response/tolerance to IFX, tapering strategy, and in a subsequent treatment with a second tumor necrosis factor inhibitor (TNFi). Methods: A prospective cohort of 60 patients with radiographic axial spondyloarthritis who received IFX were evaluated retrospectively regarding clinical/laboratorial data, IFX levels, and anti‐IFX antibodies at baseline, after 6, 12 to 14, 22 to 24, 48 to 54, 96 to 102 weeks, and before tapering or switching. Results: Anti‐IFX antibodies were detected in 27 patients (45%), of whom 23 (85.1%) became positive in the first year of IFX treatment. In comparison to the group that was negative for anti‐IFX antibodies, patients who were positive for anti‐IFX antibodies demonstrated the following: less use of methotrexate as a concomitant treatment to IFX (5 [18.5%] vs 14 [42.4%]; P = 0.048), more infusion reactions at 22 to 24 weeks (P = 0.020) and 48 to 54 weeks (P = 0.034), more treatment failures (P = 0.028) at 48 to 54 weeks, reduced overall IFX survival (P < 0.001), and lower sustained responses (P = 0.044). Of note, patients who were positive for anti‐IFX antibodies exhibited a shorter tapering survival (9.9 months [95% confidence interval (CI) 4.0–15.8] vs 63.4 months [95% CI 27.9–98.8]; P = 0.004) in comparison with patients who were negative for anti‐IFX antibodies. Conversely, for patients who failed IFX, patients who were positive for anti‐IFX antibodies had better clinical response to the second TNFi at three months (15 [83.3%] vs 3 [27.3%]; P = 0.005) and six months (15 [83.3%] vs 4 [36.4%]; P = 0.017) than the patients who were negative for anti‐IFX antibodies after switching. Conclusion: This study provided novel data that anti‐IFX antibodies is a parameter for reduced tapering survival, reinforcing its detection to guide clinical decision. Additionally, we confirmed in a long‐term cohort the anti‐IFX antibody association with worse IFX performance and as predictor of the second TNFi good clinical response. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis.

Author

Brunner, Hermine I, Ruperto, Nicolino, Ramanan, Athimalaipet V, Horneff, Gerd, Minden, Kirsten, Penades, Inmaculada Calvo, Alexeeva, Ekaterina, Cleary, Gavin, Stern, Sara M, Kone-Paut, Isabelle, Velázquez, María del Rocío Maldonado, Rabinovich, C Egla, Remesal, Agustin, Silva, Clovis Artur, Nikishina, Irina, Zucchetto, Mauro, Brockwell, Laura, Gordon, Oliver, Nagel, Sandra, and Benedetti, Fabrizio De

Subjects
THERAPEUTIC use of monoclonal antibodies, JUVENILE idiopathic arthritis, PATIENT safety, RESEARCH funding, CLINICAL trials, DESCRIPTIVE statistics, MONOCLONAL antibodies, DRUG efficacy, TOCILIZUMAB, SUBCUTANEOUS injections, INTERLEUKINS, EVALUATION, CHILDREN
Abstract

Objective To investigate the safety and efficacy of subcutaneous tocilizumab (SC-TCZ) treatment in a long-term extension (LTE) of clinical trials in polyarticular or systemic juvenile idiopathic arthritis (pJIA or sJIA). Methods Patients with pJIA or sJIA from two open-label, 52-week phase 1b core trials of SC-TCZ who had adequate response per investigator assessment entered the LTE and continued SC-TCZ treatment according to body weight–based dosing regimens until commercial availability or up to 5 years. Pharmacokinetics, pharmacodynamics, and efficacy were assessed for up to 3 years, and safety for up to 5 years in the LTE. Results Forty-four patients with pJIA and 38 patients with sJIA entered the LTE. Tocilizumab trough concentrations were maintained within the range expected to provide clinical benefit (mean values: pJIA, ∼10 μg/ml; sJIA, ∼75 μg/ml over 3 years). Pharmacodynamic parameters (interleukin-6, soluble interleukin-6 receptor, erythrocyte sedimentation rate, C-reactive protein) were maintained throughout the LTE at levels achieved in the core trials. Inactive disease per American College of Rheumatology provisional criteria was reported for 90% (17/19) and 53% (8/15) of patients with pJIA and 91% (10/11) and 92% (12/13) of patients with sJIA in the <30 and ≥30 kg body weight groups, respectively. Serious adverse events in the LTE were reported in six patients with pJIA (13.6%; five serious infections) and five patients with sJIA (13.2%; one serious infection). Conclusion Patients with pJIA or sJIA experienced long-term disease control with SC-TCZ treatment. Long-term safety was consistent with the known tocilizumab safety profile. Clinical trial registration clinicaltrials.gov, NCT02165345 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study

Author

Aikawa, Nadia E, Kupa, Leonard V K, Pasoto, Sandra G, Medeiros-Ribeiro, Ana C, Yuki, Emily F N, Saad, Carla G S, Pedrosa, Tatiana, Fuller, Ricardo, Shinjo, Samuel K, Sampaio-Barros, Percival D, Andrade, Danieli C O, Pereira, Rosa M R, Seguro, Luciana P C, Valim, Juliana M L, Waridel, Filipe, Sartori, Ana Marli C, Duarte, Alberto J S, Antonangelo, Leila, Sabino, Ester C, Menezes, Paulo Rossi, Kallas, Esper G, Silva, Clovis A, and Bonfa, Eloisa

Published
2022
Full Text
View/download PDF

34. Long‐term follow‐up of anti‐infliximab antibodies in radiographic axial spondyloarthritis patients: a marker of drug survival and tapering

Author

Pimentel, Clarissa Q., primary, Medeiros‐Ribeiro, Ana Cristina, additional, Shimabuco, Andrea Y., additional, Sampaio‐Barros, Percival D., additional, Moraes, Júlio César B., additional, Schainberg, Claudia G., additional, Gonçalves, Celio Roberto, additional, Leon, Elaine P., additional, Kupa, Léonard De Vinci K., additional, Pasoto, Sandra G., additional, Aikawa, Nádia E., additional, Silva, Clovis A., additional, Bonfa, Eloisa, additional, and Saad, Carla G. S., additional

Published
2024
Full Text
View/download PDF

37. KNN Applied to PDG for Source Code Similarity Classification

Author

Silva, Clóvis Daniel Souza, Ferreira da Costa, Leonardo, Rocha, Leonardo Sampaio, Viana, Gerardo Valdísio Rodrigues, Goos, Gerhard, Founding Editor, Hartmanis, Juris, Founding Editor, Bertino, Elisa, Editorial Board Member, Gao, Wen, Editorial Board Member, Steffen, Bernhard, Editorial Board Member, Woeginger, Gerhard, Editorial Board Member, Yung, Moti, Editorial Board Member, Cerri, Ricardo, editor, and Prati, Ronaldo C., editor

Published
2020
Full Text
View/download PDF

38. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial

Author

Medeiros-Ribeiro, Ana C., Aikawa, Nadia E., Saad, Carla G. S., Yuki, Emily F. N., Pedrosa, Tatiana, Fusco, Solange R. G., Rojo, Priscila T., Pereira, Rosa M. R., Shinjo, Samuel K., Andrade, Danieli C. O., Sampaio-Barros, Percival D., Ribeiro, Carolina T., Deveza, Giordano B. H., Martins, Victor A. O., Silva, Clovis A., Lopes, Marta H., Duarte, Alberto J. S., Antonangelo, Leila, Sabino, Ester C., Kallas, Esper G., Pasoto, Sandra G., and Bonfa, Eloisa

Published
2021
Full Text
View/download PDF

43. Physical Activity: A Strategy to Improve Antibody Response to a SARS-CoV-2 Vaccine Booster Dose in Patients With Autoimmune Rheumatic Diseases.

Author

Gualano, Bruno, Sieczkowska, Sofia M., Lemes, Ítalo Ribeiro, da Silva, Rafael Pires, Pinto, Ana J., Mazzolani, Bruna C., Smaira, Fabiana I., Aikawa, Nadia E., Kupa, Leonard V.K., Pasoto, Sandra G., Medeiros-Ribeiro, Ana C., Saad, Carla G.S., Yuk, Emily F.N., Silva, Clovis A., Swinton, Paul, Hallal, Pedro C., Roschel, Hamilton, and Bonfa, Eloisa

Subjects
BOOSTER vaccines, COVID-19 vaccines, RHEUMATISM, ANTIBODY formation, PHYSICAL activity, HIV seroconversion
Abstract

Background: Physical activity associates with improved immunogenicity following a 2-dose schedule of CoronaVac (Sinovac's inactivated SARS-CoV-2 vaccine) in patients with autoimmune rheumatic diseases (ARD). This study evaluates whether physical activity impacts vaccine-induced antibody responses to a booster dose in this population. Methods: This was a phase-4 trial conducted in São Paulo, Brazil. Patients with ARD underwent a 3-dose schedule of CoronaVac. One month after the booster, we assessed seroconversion rates of anti-SARS-CoV-2 S1/S2 IgG, geometric mean titers of anti-S1/S2 IgG, frequency of positive neutralizing antibodies, and neutralizing activity. Physical activity was assessed through questionnaire. Results: Physically active (n = 362) and inactive (n = 278) patients were comparable for most characteristics; however, physically active patients were younger (P <.01) and had a lower frequency of chronic inflammatory arthritis (P <.01). Adjusted models showed that physically active patients had ∼2 times odds of seroconversion rates (OR: 2.09; 95% confidence interval, 1.22 to 3.61), ∼22% greater geometric mean titers of anti-S1/S2 IgG (22.09%; 95% confidence interval, 3.91 to 65.60), and ∼7% greater neutralizing activity (6.76%; 95% confidence interval, 2.80 to 10.72) than inactive patients. Conclusions: Patients with ARD who are physically active have greater odds of experiencing better immunogenicity to a booster dose of CoronaVac. These results support the recommendation of physical activity to improve vaccination responses, particularly for immunocompromised individuals. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Puberty in girls with Prader-Willi syndrome: cohort evaluation and clinical recommendations in a Latin American tertiary center.

Author

Buff Passone, Caroline Gouveia, Ferrer Aragão, Luciana Felipe, Franco, Ruth Rocha, Simioni Leite, Junia Ellen, Benitez Gonzalez, Michelle Antonella, de Albuquerque Schil, Priscila Schuindt, Ybarra, Marina, Damiani, Durval, Kerkhof, Gerthe Femke, Montenegro Junior, Renan Magalhães, and Silva, Clovis Artur

Subjects
PUBERTY, PRADER-Willi syndrome, AGE, BODY mass index, HORMONE therapy, PEDIATRIC endocrinology
Abstract

Introduction: Prader-Willi syndrome (PWS) is a genetic disorder characterized by hypothalamic-pituitary deficiencies including hypogonadism. In girls with PWS, hypogonadism can present early in childhood, leading to genital hypoplasia, delayed puberty, incomplete pubertal development, and infertility. In contrast, girls can present with premature activation of the adrenal axis leading to early pubarche and advanced bone age. We aim to evaluate the progression of puberty and adrenarche signals in girls with PWS. Methodology: A longitudinal retrospective cohort study included girls with PWS followed at a Pediatric Endocrinology Outpatient Clinic in a Tertiary University Hospital in Sao Paulo, Brazil from 2002 to 2022. Data collected via chart review included clinical information on birth history, breast and pubic hair Tanner stages, presence of genital hypoplasia, age at menarche, regularity of menstrual cycles, body mass index (BMI) z-score, final height, age of initiation of estrogen replacement and growth hormone replacement, as well as results for PWS genetic subtype; biochemical investigation (LH, FSH, estradiol, DHEA-S); radiographic bone age and pelvic ultrasound. Results: A total of 69 girls were included in the study and the mean age of puberty onset was 10.2 years in those who started puberty after the age of 8 years. Breast Tanner stage IV was reached by 29.1% girls at a mean age of 14.9 years. Spontaneous menarche was present in 13.8% and only one patient had regular menstrual cycles. Early adrenarche was seen in 40.4% of cases. Conclusion: Our study demonstrated in a large sample that girls with PWS often present with delayed onset of puberty despite frequent premature adrenarche. Based on our results, we suggest an estrogen replacement protocol for girls with PWS to be started at the chronological age or bone age of 12–13 years, taking into consideration the uterus size. Further prospective studies are needed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

46. Data-driven, cross-disciplinary collaboration: lessons learned at the largest academic health center in Latin America during the COVID-19 pandemic

Author

Ritto, Ana Paula, primary, de Araujo, Adriana Ladeira, additional, de Carvalho, Carlos Roberto Ribeiro, additional, De Souza, Heraldo Possolo, additional, Favaretto, Patricia Manga e Silva, additional, Saboya, Vivian Renata Boldrim, additional, Garcia, Michelle Louvaes, additional, Kulikowski, Leslie Domenici, additional, Kallás, Esper Georges, additional, Pereira, Antonio José Rodrigues, additional, Cobello Junior, Vilson, additional, Silva, Katia Regina, additional, Abdalla, Eidi Raquel Franco, additional, Segurado, Aluisio Augusto Cotrim, additional, Sabino, Ester Cerdeira, additional, Ribeiro Junior, Ulysses, additional, Francisco, Rossana Pulcineli Vieira, additional, Miethke-Morais, Anna, additional, Levin, Anna Sara Shafferman, additional, Sawamura, Marcio Valente Yamada, additional, Ferreira, Juliana Carvalho, additional, Silva, Clovis Artur, additional, Mauad, Thais, additional, Gouveia, Nelson da Cruz, additional, Letaif, Leila Suemi Harima, additional, Bego, Marco Antonio, additional, Battistella, Linamara Rizzo, additional, Duarte, Alberto José da Silva, additional, Seelaender, Marilia Cerqueira Leite, additional, Marchini, Julio, additional, Forlenza, Orestes Vicente, additional, Rocha, Vanderson Geraldo, additional, Mendes-Correa, Maria Cassia, additional, Costa, Silvia Figueiredo, additional, Cerri, Giovanni Guido, additional, Bonfá, Eloisa Silva Dutra de Oliveira, additional, Chammas, Roger, additional, de Barros Filho, Tarcisio Eloy Pessoa, additional, and Busatto Filho, Geraldo, additional

Published
2024
Full Text
View/download PDF

47. Autoinflammatory diseases: a Latin American multicenter study according to age and sex

Author

Piotto, Daniela Gerent Petry, primary, Kozu, Katia, additional, Aikawa, Nádia Emi, additional, Carneiro, Pedro Lopes, additional, Katsicas, María Martha, additional, Oliveira, Sheila Knupp Feitosa de, additional, Fernandes, Taciana de Albuquerque Pedrosa, additional, Magalhães, Claudia Saad, additional, Cunha, Ana Luiza Garcia, additional, Bica, Blanca Elena Rios Gomes, additional, Rabelo Júnior, Carlos Nobre, additional, Battagliotti, Cristina, additional, Matos, Erica Naomi Naka, additional, Santos, Flavia Patrícia Sena Teixeira, additional, Sztajnbok, Flavio Roberto, additional, Bezrodnik, Liliana, additional, Bandeira, Marcia, additional, Rodrigues, Marta Cristine Felix, additional, Munittis, Pablo García, additional, Appenzeller, Simone, additional, Robazzi, Teresa Cristina Martins, additional, Clemente, Gleice, additional, Silva, Clovis Artur, additional, and Terreri, Maria Teresa, additional

Published
2024
Full Text
View/download PDF

48. Comparison of EULAR/PRINTO/PReS Ankara 2008 and 2022 ACR/EULAR Classification Criteria for Granulomatosis with Polyangiitis in Children

Author

Kaya Akca, Ummusen, primary, Batu, Ezgi Deniz, additional, Jelusic, Marija, additional, Calatroni, Marta, additional, Bakry, Reima, additional, Frkovic, Marijan, additional, Vinšová, Nikol, additional, Campos, Reinan T, additional, Horne, AnnaCarin, additional, Caglayan, Sengul, additional, Vaglio, Augusto, additional, Moroni, Gabriella, additional, Emmi, Giacomo, additional, Ghiggeri, Gian Marco, additional, Koker, Oya, additional, Sinico, Renato Alberto, additional, Kim, Susan, additional, Gagro, Alenka, additional, Matucci-Cerinic, Caterina, additional, Çomak, Elif, additional, Ekici Tekin, Zahide, additional, Arslanoglu Aydin, Elif, additional, Heshin-Bekenstein, Merav, additional, Acar, Banu Celikel, additional, Gattorno, Marco, additional, Akman, Sema, additional, Sozeri, Betul, additional, Palmblad, Karin, additional, Al-Mayouf, Sulaiman M, additional, Silva, Clovis Artur, additional, Doležalová, Pavla, additional, Merkel, Peter A, additional, and Ozen, Seza, additional

Published
2023
Full Text
View/download PDF

49. Development of clinical and laboratory biomarkers in an international cohort of 428 children with lupus nephritis

Author

De Mutiis, Chiara, primary, Wenderfer, Scott, additional, Basu, Biswanath, additional, Bagga, Arvind, additional, Orjuela, Alvaro, additional, Sar, Tanmoy, additional, Aggarwal, Amita, additional, Jain, Avinash, additional, Boyer, Olivia, additional, Yap, Hui-Kim, additional, Ito, Shuichi, additional, Ohnishi, Ai, additional, Iwata, Naomi, additional, Kasapcopur, Ozgur, additional, Laurent, Audrey, additional, Chan, Eugene, additional, Mastrangelo, Antonio, additional, Ogura, Masao, additional, Shima, Yuko, additional, Rianthavorn, Pornpimol, additional, Silva, Clovis, additional, Trindade, Vitor, additional, and Tullus, Kjell, additional

Published
2023
Full Text
View/download PDF

50. Impaired cardiorespiratory fitness and endothelial function after SARS-CoV-2 infection in a sample of mainly immunocompromised youth

Author

Astley, Camilla, primary, Prado, Danilo Marcelo Leite do, additional, Sieczkowska, Sofia Mendes, additional, Esteves, Gabriel P., additional, Suguita, Priscila, additional, Fink, Thais, additional, Lindoso, Livia, additional, Matsuo, Olivia, additional, Martins, Fernanda, additional, Bain, Vera, additional, Badue Pereira, Maria Fernanda, additional, Marques, Heloisa Helena, additional, Malluf, Adriana, additional, Leal, Gabriela Nunes, additional, Silva, Clovis Artur, additional, Roschel, Hamilton, additional, and Gualano, Bruno, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results